for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising—nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with—an anti CD30 antibody, such as brentuximab vedotin...
(生物谷Bioon.com) 原文出处:U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma 免责声明:本文仅作信息交流,文中的观点不代表立场,亦不代表中肽生化支持...
Analysis of bulk RNA sequencing data from the patients suggested that the triplet combination enhanced CD8+ T cell infiltration, resulting in a more immunologically active tumor microenvironment. Our study suggests that the combination of a PD-1 antibody, an HDACi, and a VEGF antibody could be a...
Dual targeting by bispecific/bifunctional antibodies has emerged as an option for combination therapy. Bispecific/bifunctional antibody simultaneously blocks two molecules with one drug, having a strategic advantage over the combination therapy (Table7) [277]. Table 7 Bispecific/bifunctional antibodies targe...
Either blocking CD25 with an antibody or using a mutated version of IL-2 that does not bind to CD25 but still binds to CD122 and CD132 almost completely abrogated the synergistic effects observed after PD-1 + IL-2 combination therapy. There is considerable interest in PD-1 + IL-2 ...
Glioma treatment using a PD-1/PD-L1 blocking antibody Combination therapy strategy and preclinical research The blockade of PD-1/PD-L1 can elicit effective anti-tumor T cell responses. In the past 5 years, the targeting of the PD-1/PD-L1 axis has been at the forefront of immunotherapy due...
原文出处:U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma ...
[2] Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Mela...
PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum: Two case reports. World J Clin Oncol 2024; 15(3): 456-463 URL: https://www.wjgnet.com/2218-4333/full/v15/i3/456.htm DOI: https://dx.doi.org/...
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial Article Open access 03 February 2024 Introduction In the spirit of the Hippocratic dictum to “first, do no harm...